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ABSTRACT
Objective: The objective for this selective EMB review is to determine whether or not the reduction
of caffeine intake is effective in reducing the symptoms of panic attack in panic disorder patients.
Study Design: Review of three English language randomized control trials published in 2007, 2008,
and 2009.
Data Sources: The double-blind placebo-controlled randomized control trials were obtained via
PubMed.
Outcomes Measured: The prevalence of a clinical panic attack. Pre and post caffeine/placebo
administration questionnaires were given to the participants. These surveys included the Subjective
Units of Disturbance Scale (SUDS) and the Diagnostic Symptom Questionnaire (DSQ). These studies
were modified for use with the DSM-IV definition of a panic attack.
Results: None of the patients who ingested the placebo showed evidence of a clinical panic attack.
This was a consistent finding in all three studies. A panic attack was not experienced by any of the
control subjects in the 2008 and 2009 studies. Two of the control subjects experienced a panic attack
in the 2007 study after ingestion of caffeine. Finally, the panic disorder patients experienced a panic
attack at frequencies of 60.7%, 52.0%, and 58.6%, in each of the studies, after administration of
480mg of caffeine.
Conclusions: All three studies showed sufficient association of ingestion of 480mg of caffeine with
the induction of a clinical panic attack those afflicted with panic disorder. Although there is strong
evidence showing that ingestion of caffeine in a patient with a panic induces a panic attack, there is
no evidence showing that abstinence from this chemical reduces panic attack incidence. This is due to
the fact that no credible scientific studies have yet been designed to show this information.
Key Words: Panic Disorder, Panic Attacks, Anxiety Disorder, Caffeine
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INTRODUCTION
Panic Disorder is a condition defined by erratic episodes of profound anxiety, coupled with
physical signs and symptoms, also known as panic attacks1. These signs and symptoms include chest
pain, palpitations, profuse sweating, shaking, difficulty concentrating, shortness of breath, choking
sensation, abdominal discomfort, fear of dying, and sensing a loss of control2. Not only can these
symptoms be physically uncomfortable, they can also interfere with a person’s daily activities.
Oftentimes a patient afflicted with this spectrum of symptoms fears having a panic attack, especially
in public, and will go to extreme lengths to avoid being in public when the attack comes on1. For this
reason, these patients often develop a fear of being in public, let alone leaving their own homes.
Because it is often difficult or impossible for this person to predict when they will have another
“attack”, there is a secondary development of agoraphobia, or the fear of being in public places1. In
addition to the timing being unpredictable, the frequency of attack is also unpredictable. These panic
attacks can come as frequently as multiple times per day, or as little as a few per year1. This all fuels
the uncertainty and further anxiety surrounding panic disorder patients. The symptom profile and
subsequent secondary illness attest to the severity of this mental illness and the patient’s need to
receive proper treatment.
Physician Assistants should be comfortable with the diagnosis and treatment of this anxiety
disorder for multiple reasons. One of the reasons for concern is the epidemiology of this disease.
Panic Disorder is estimated to affect 2.7% of adults in the United States, at an estimated 6 million
people3. There is a lifetime prevalence of 1-3%, with a slight predominance in female patients4.
These statistics attest to the importance of awareness by Physician Assistants, as well as the medical
community. Patients often present first to their primary care provider seeking treatment for mental
illness before reaching out to mental health specialists. This is one reason why Physician Assistants
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need to be aware of current treatment recommendations. Another point of importance is the cost of
care for this specific patient population. Exact numbers for the cost of panic disorder management
worldwide are not available; however, the cost of mental health care for all Americans in 2006 was
found to be 57.5 billion dollars5, with a large percentage of those dollars being allotted for the
treatment of anxiety disorders5. These staggering numbers also demonstrate the need for awareness
and support of mental health amongst health care providers. A final rationale for support of this
disease is the number of healthcare visits per year related to the spectrum of symptoms and secondary
issues. Although there is no current data showing the number of health care visits per year for
treatment of panic disorder, multiple studies have shown that patients affected by panic disorder
present to their primary care physicians 3-5 times more than the average person, and to the
emergency department 6 times as often5. This trend is thought to be due to the similarity of symptoms
shared by panic attacks and other cardiovascular or respiratory conditions7. This data further supports
the need for appreciation and knowledge of panic disorder amongst Physician Assistants.
Like many other mental illnesses, the exact etiology of panic disorders is unknown; however,
there have been multiple studies that link certain genetic abnormalities, as well as various
environmental changes, to the root cause of panic disorder1. One theory proposes that lactate levels
may somehow play a role, as a result of a study that showed induction of a panic attack in known
panic disorder patients after the infusion of lactate4. Another possible etiology involves abnormally
elevated noradrenergic impulses to the locus coeruleus6. Both etiologies can result in a type of
malfunction of the nervous system in this patient population. There is also a known disruption of
serotonin, norepinephrine, and/or ƴ-aminobutryic acid (GABA) levels in these patients, most
demonstrated by a high positive response to drugs formulated to alleviate the dysfunctions in these
neurotransmitter levels1. Furthermore, MRI studies have shown involvement of the temporal lobes
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during panic attacks, most notably in the amygdala and hippocampus regions1. Because the etiology
is still not entirely understood, there is continued room for research on treatments for this patient
population.
There are a number of treatments designed to reduce the symptoms experienced by those
afflicted with panic disorder. The mainstay of treatment as approved by the FDA for this disorder is
either Xanax (Alprazolam) or Paxil (paroxetine)1. Though Xanax is a sufficient option, there is
growing evidence to support of the use of selective serotonin re-uptake inhibitors (SSRIs), such as
Paxil, for treatment of panic disorder1. Any of the SSRIs are a viable option for treatment, though
Paxil is the one specifically approved by the FDA for this use and has the quickest onset of action of
the SSRIs1. One down-side to the use of SSRIs for mono-therapy is that many of these drugs take
time to build therapeutic doses in the patient’s system4. For this reason, it may be indicted to use a
drug such as Xanax as a supplemental therapy until sufficient doses of SSRIs can be achieved4. If a
patient fails to respond to treatment with one of the first line agents, clinicians should try other SSRIs
or benzodiazepines (Xanax)1. If the patient fails to respond to repeated attempts at treatment with
mono-therapy, health care providers can do a trial of combination medications, such as an SSRI and a
benzodiazepine1.
Though there is no cure for panic disorder, effective control of the symptoms is a realistic
goal5. Despite the existence of efficacious treatments for panic disorder symptoms, there continues to
be an effort to find alternatives with a lower side-effect profiles and higher rates of symptom
alleviation. Any medication will carry its own set of adverse reactions and intolerability for various
reasons. Anytime a lifestyle modification can be suggested that helps alleviate symptoms or decrease
severity of the disease, there is less of a burden on the patient. Because caffeine has long been known
as a psychoactive chemical, resulting in alterations of mood and central nervous system functioning7,

Wasson, Panic Disorder and Caffeine,
it is suggested as a possible etiology of anxiety disorders and panic disorder1. Caffeine has in fact
been identified as a “panicogen”, or a chemical believed to induce panic attacks, in a patient with an
existing panic disorder1. Until recently, though, there has been insufficient evidence to show such
relations between caffeine ingestion and induction of a clinical panic attack. Elimination of certain
elements from one’s diet has shown to make marked improvement in a patient’s disease severity in
several instances. For example, a patient’s reduction of sodium intake has shown to decrease the
intensity of a patient’s hypertension4. If a chemical agent has been shown to induce panic attacks, it
can be logically assumed that elimination of this panicogen from a panic disorder patient’s diet may
help improve the frequency of attacks and severity of symptoms. It is for this reason that several
randomized control trials have been carried out in attempt to scientifically show a relationship
between caffeine ingestion and induction of a clinical panic attack.
OBJECTIVE
The objective for this selective EMB review is to determine whether or not the reduction of
caffeine intake is effective in reducing the symptoms of panic attack in panic disorder patients.
METHODS
Certain criteria were put in place for selection of the proper research to ascertain consistent,
controlled results. The population used included adult patients between the ages of 18-55 with an
existing diagnosis of panic disorder. The studies used for this systematic review were required to be
double-blind, placebo controlled, randomized control trials. The intervention was a 480mg caffeine
challenge, with the placebo being a visually matched decaffeinated coffee solution. The placebo was
administered to a control group that was without the diagnosis of panic attack. The measured
outcome was the incidence of a panic attack within 30 minutes of caffeine ingestion.

5
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In order to conjure the studies included in this analysis, a thorough search of randomized
control trials was carried out between December 2011 and February 2012 via PubMed. All articles
were published in peer reviewed journals and published in the English language. The key words used
in the search were “panic disorder”, “panic attacks”, “anxiety disorder”, and “caffeine.” The articles
selected for this systematic review also had to fit the criteria of Patient Oriented Evidence that
Matters (POEMs). The inclusion was that of randomized, controlled, double blind, and placebo
controlled studies published after 1997. The exclusion criteria included studies using patients under
the age 18 and those over the age 55, as well as disease-oriented evidence (DOE) studies. Any studies
published before the year 1997 were excluded from consideration. Furthermore, any patients who
reported taking anti-anxiety medication within the past 3 weeks were excluded from the study.
Patients also had to agree to abstinence from caffeine for 1 week prior to the study. All studies used
reported p-values, which were used to convert the data to Relative Risk Reduction (RRR), Absolute
Risk Reduction (ARR), and Numbers Needed to Treat (NNT).
A summary of the demographics included in these studies is provided below in Table 1:

OUTCOMES MEASURED:
Outcomes were measured largely on the basis on patient reporting, as well as through
physician reporting. Pre- and post-caffeine/placebo administration questionnaires were given to
the participants. The pre-test questionnaire was administered just before the caffeine distribution.
The post-test surveys were given at 15 minutes and again at 30 minutes after ingestions of the
solutions. These surveys included the Subjective Units of Disturbance Scale (SUDS) and the
Diagnostic Symptom Questionnaire (DSQ)2,7,8. These studies were modified for use with the
DSM-IV definition of a panic attack.
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Table 1: Demographics and Characteristics of Included Studies
Study

Type

# Pts

Nardi
(2009)8

Doubleblind
RCT

98

Age
(years)
18-55

Nardi
(2008)7

Doubleblind
RCT

74

18-55

Doubleblind
RCT

109

Nardi
(2007)2

Inclusion Criteria

Exclusion Criteria

W/D

Interventions

Patients 18-55 years of age,
occurrence of three panic
attacks in two weeks before
the first challenge test day
for the panic disorder
patients, no use of any
antipsychotic,
antidepressant,
benzodiazapine, or
nonbenzodiazepine
anxiolytic medication for at
least four weeks, or
fluoxetine for 5 weeks,
before the first test by any
subject, and a negative urine
test for benzodiazepines and
other medications just
before each challenge test.

Patients aged less
than 18 or older
than 55; Unstable
medical condition,
cognitive-behavior
psychotherapy
during the study,
or the presence of
suicidal risk,
history of
respiratory
disease, and
smokers.

0

A 480mg
caffeine
challenge

0

A 480mg
caffeine
challenge

0

A 480mg
caffeine
challenge

(See above inclusion
criteria)

(See above
exclusion criteria)

18-55

(See above inclusion
criteria)

(See above
exclusion criteria)

The SUDS required the patients to rate their level of anxiousness on a scale of 0-10, with 0
being no anxiety and a 10 being the worst anxiety imaginable. The DSQ required four or more of the
following symptoms, identified through patient reporting: fear of dying, chest pain/discomfort,
shortness of breath, paresthesias, feelings of choking, dizziness/lightheadedness, depersonalization/
derealization, losing control/going crazy, chills/hot flushes, nausea/abdominal distress, palpitations,
sweating, and trembling/shaking. Furthermore, the test subjects had to show evidence of at least one
of the following cognitive panic symptoms: fear of dying, losing control, or “going crazy.2” Patients
also had to report their own sensation of “panic or fear” in order to be considered as a true panic
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attack responder. All of these responses were rated on a scaled of 0-4 by the patients, with 0 being no
symptoms experienced and a 4 being the most severe form of that symptom. In addition to the
patient’s own reporting, two medical doctors had to be in agreement that the patient was experiencing
a true panic attack. The thorough questionnaires, as well as the input required by a medical doctor,
helps to rule out any cases of malingering or false reporting on the part of the patient. Important to
note was that the SUDS was not used to clinically diagnose a panic attack; however, the information
obtained from the SUDS provided valuable information to support the validity of the patients own
experience.

RESULTS:
All three randomized control trials evaluated in this systematic review compared the effect of
caffeine administration on patients with existing diagnosis of panic disorder. None of the participants
withdrew from the study in any of the three articles. All three studies found a positive correlation
between caffeine administration and induction of a panic attack in patients previously diagnosed
panic disorder.
The Nardi, et al 2007 study2 found statistically significant data showing the correlation
between caffeine ingestion and the resulting clinically determined panic attack. This study involved
29 patients with panic disorder, 27 patients with panic disorder accompanied by major depressive
disorder, 25 patients with major depressive disorder (without panic disorder), and 28 control patients
without any psychological diagnosis. For the purposes of this review, no information is being
reported concerning the patients with major depressive disorder with or without panic disorder. In the
panic disorder group, 17 of the 29 patients, or 56.6%, experienced a clinical panic attack within 30
minutes of ingestion of the caffeine solution. This study was the only one of the three articles to
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report 7.1% (2 patients) of the control subjects experiencing a panic attack after ingestion of the
480mg of caffeine. None of the patients who were given the caffeine-free solution experienced a
panic attack. This study also showed, therefore, that for every two persons treated with this
intervention, one would benefit.

Table 2: Nardi, et al 2007 study2 showing incidence of panic attack in panic disorder patients
after administration of 480mg of caffeine:
CER
EER
RRR
ARR
NNT
p-value
0.07

0.58

7.25

0.51

2

<0.001

The Nardi, et al 2008 study7 also found statistically significant data showing the correlation
between caffeine ingestion and a subsequent clinically determined panic attack. This study involved
25 patients with panic disorder, 27 health patients that were first-degree relatives of the each panic
disorder patient, and 22 control patients without any psychological diagnosis. For the purposes of this
review, no information is being reported concerning the first degree relatives. This study found that
13 of the 25, or 52.0%, panic disorder patients experienced a panic attack after ingestion of the
caffeine solution. None of the control subjects experienced a panic attack after ingestion of the
caffeine solution. None of the subjects experienced a panic attack after ingestion of the placebo
solution. This study also showed that approximately 1 in 2 patients would benefit this treatment type.
Table 3: Nardi, et al 2008 study7 showing the incidence of panic attack in panic disorder patients
after administration of 480mg of caffeine
CER
EER
RRR
ARR
NNT
p-value
0.00

0.52

____

0.52

2

<0.001
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The Nardi, et al 2009 study8 again found statistically significant data showing the correlation
between caffeine ingestion and the resulting clinically determined panic attack. This study involved
28 patients with panic disorder, 25generalized social anxiety patients, 19 patients with performance
social anxiety disorder, and 26 control patients without any psychological diagnosis. For the purposes
of this review, no information is being reported concerning the patients with generalized social
anxiety or performance social anxiety. In the panic disorder group 17 of the 28, or 60.7%, panic
disorder patients experienced a panic attack after administration of the 480mg caffeine solution. None
of the control subjects experienced a panic attack after ingestion of the caffeine solution. None of the
patients, control or PD, experienced a panic attack after ingestion of the placebo solution. This study
again showed that approximately 1 in 2 patients would benefit from this treatment.
Table 4: Nardi 2008 study showing the incidence of panic attack in panic disorder patients after
administration of 480mg of caffeine
CER
EER
RRR
ARR
NNT
p-value
0.00

0.61

____

0.61

2

<0.001

The data in all three studies was collected on two different occasions, seven days apart from
the preceding study. There was no follow up reporting to be collected from the participants. No harm
can be found in patients withdrawing from caffeine ingestion, as caffeine is an unnecessary
component in one’s diet.

DISCUSSION:
This systematic review comprised of three double blind, placebo controlled, randomized
control trials on the effect of caffeine ingestion and induction of a panic attack in those with panic
disorder. Panic disorder is a serious mental illness that affects millions of people in the United States;
therefore, a safe and effective treatment for symptom management is indispensable. All of the studies
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conducted between 2007 and 2009 by the Laboratory of Panic and Respiration Institute of Psychiatry
in Rio de Janeiro, Brazil revealed of numbers needed to treat of 2, which attests to the impact of
caffeine on panic disorder patients’ symptoms.
There are a limited number of studies concerning the direct administration of caffeine to panic
disorder patients, perhaps due to the ethical implications of the intervention. Because of this, the
Nardi trials were three of the most outstanding and relevant studies to this topic. The downside to all
three of these articles being produced by the same research facility is that the data is subject to
perhaps a larger degree of bias. For example, since the study was conducted in Brazil, only those of
Brazilian ethnicity were considered in all three studies. This is perhaps one of the greatest limitations
of this review, under the argument that certain ethnic groups are more subject to certain diseases than
others and may therefore react differently to certain interventions or treatments. Along these same
lines, the authors of these articles mention that coffee is a very important beverage to the culture of
the Brazilians, implying perhaps a greater dependence on caffeine than may exist for other patient
ethnicities.
Another limiting factor in this analysis is that only the ingestion of 480mg was studied.
Because patients naturally consume varying amounts of caffeine, we do not know how lower
amounts of caffeine may impact a patient with panic disorder.
Further limitation includes the age restrictions of the three studies. The research team only
included patients over the age of 18 years old and under the age of 55. Although patients younger
than the selection criteria are not as known for their caffeine dependency, people younger than 18 do
ingest caffeine and could perhaps benefit from this intervention. Subsequently, patients over the age
of 55 consume caffeine in various forms and can still be afflicted by panic attacks. For this reason,
the age selection from these studies can be considered a limiting factor to the use of this information.
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Another argument can be made for the size of the patient populations. Each of the studies only
involved 22-28 panic disorder patients. Although it can be difficult to obtain willing, consented
patients for this study, a larger sample size may have resulted in higher or lower percentages of
effect.

CONCLUSION:
Although there is strong evidence showing that ingestion of caffeine in a patient with a panic
induces a clinical panic attack, there is no evidence showing that abstinence from this chemical
reduces panic attack incidence. The evidence is inconclusive concerning the reduction of caffeine
intake as an effective treatment for the reduction of the symptoms of panic attack in panic disorder
patients. In order to obtain results to satisfy this question, a study should perhaps be designed
involving existing caffeine consuming panic disorder patients who are then withdrawn from caffeine
for a period of time and monitored for incidence of panic attacks. Additionally, further studies should
be set up to involve patients of varying ethnicity and age to ensure that this is an effective treatment
for any caffeine-consuming person. Because there is relatively no harm in having a patient withdraw
from caffeine, clinicians should have no hesitation in recommending this as a part of a treatment plan
to patients; they must be informed, however, that there has yet to be clinical evidence showing the
efficacy of this as a treatment. Furthermore, if a patient did not already consume caffeine before his
diagnosis with panic disorder, this treatment becomes irrelevant. Further research is warranted to
confirm caffeine withdrawal an effective treatment for panic disorder patients.
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